Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
39
IART Quote, Financials, Valuation and Earnings
Last price:
$12.42
Seasonality move
:
9.88%
Day range:
$12.38 - $12.73
52-week range:
$10.87 - $27.13
Dividend yield:
0%
P/E ratio:
70.14x
P/S ratio:
0.58x
P/B ratio:
0.93x
Volume:
436.8K
Avg. volume:
823.4K
1-year change:
-43.53%
Market cap:
$967.4M
Revenue:
$1.6B
EPS (TTM):
-$6.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$429.6M | $0.80 | -2.94% | 217.65% | $15.50 |
|
CLPT
Clearpoint Neuro, Inc.
|
$10.1M | -$0.20 | 29.33% | -2.56% | $29.00 |
|
IRTC
iRhythm Technologies, Inc.
|
$199.9M | $0.06 | 21.66% | -80.89% | $218.60 |
|
MASI
Masimo Corp.
|
$407.6M | $1.46 | -32.15% | 565.51% | $183.75 |
|
MMSI
Merit Medical Systems, Inc.
|
$388.3M | $0.95 | 9.51% | 106.1% | $103.60 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$276.9M | -$0.09 | -2.02% | -4.07% | $24.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$12.42 | $15.50 | $967.4M | 70.14x | $0.00 | 0% | 0.58x |
|
CLPT
Clearpoint Neuro, Inc.
|
$13.68 | $29.00 | $388.8M | -- | $0.00 | 0% | 11.16x |
|
IRTC
iRhythm Technologies, Inc.
|
$177.44 | $218.60 | $5.7B | -- | $0.00 | 0% | 8.02x |
|
MASI
Masimo Corp.
|
$130.06 | $183.75 | $7B | 116.80x | $0.00 | 0% | 4.11x |
|
MMSI
Merit Medical Systems, Inc.
|
$88.14 | $103.60 | $5.2B | 45.11x | $0.00 | 0% | 3.62x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$21.98 | $24.81 | $1.5B | -- | $0.00 | 0% | 1.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
65.91% | 0.037 | 179.84% | 1.47x |
|
CLPT
Clearpoint Neuro, Inc.
|
69.25% | 3.190 | 5.77% | 5.56x |
|
IRTC
iRhythm Technologies, Inc.
|
85.74% | 2.412 | 13.23% | 4.47x |
|
MASI
Masimo Corp.
|
41.99% | 0.887 | 7.4% | 1.68x |
|
MMSI
Merit Medical Systems, Inc.
|
34.93% | 0.094 | 16.64% | 2.67x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.942 | 54.61% | 1.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IART
Integra LifeSciences Holdings Corp.
|
$226.1M | $25.9M | -14.85% | -37.15% | 6.43% | $25.8M |
|
CLPT
Clearpoint Neuro, Inc.
|
$5.6M | -$5.3M | -60.29% | -105.19% | -59.54% | -$3.3M |
|
IRTC
iRhythm Technologies, Inc.
|
$137.1M | -$4M | -6.2% | -54.18% | -2.08% | $20.1M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
MMSI
Merit Medical Systems, Inc.
|
$186.5M | $42.8M | 5.28% | 8.28% | 11.13% | $51.5M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
Integra LifeSciences Holdings Corp. vs. Competitors
-
Which has Higher Returns IART or CLPT?
Clearpoint Neuro, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -66.48%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Clearpoint Neuro, Inc.'s return on equity of -105.19%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B CLPTClearpoint Neuro, Inc.63.2% -$0.21 $51.6M -
What do Analysts Say About IART or CLPT?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 24.8%. On the other hand Clearpoint Neuro, Inc. has an analysts' consensus of $29.00 which suggests that it could grow by 111.99%. Given that Clearpoint Neuro, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Clearpoint Neuro, Inc. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 CLPTClearpoint Neuro, Inc.2 0 0 -
Is IART or CLPT More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison Clearpoint Neuro, Inc. has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.466%.
-
Which is a Better Dividend Stock IART or CLPT?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearpoint Neuro, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Clearpoint Neuro, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or CLPT?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Clearpoint Neuro, Inc. quarterly revenues of $8.9M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is higher than Clearpoint Neuro, Inc.'s net income of -$5.9M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Clearpoint Neuro, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.58x versus 11.16x for Clearpoint Neuro, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.58x 70.14x $402.1M -$5.4M CLPTClearpoint Neuro, Inc.11.16x -- $8.9M -$5.9M
-
Which has Higher Returns IART or IRTC?
iRhythm Technologies, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -2.7%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B IRTCiRhythm Technologies, Inc.71.09% -$0.16 $854.9M -
What do Analysts Say About IART or IRTC?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 24.8%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $218.60 which suggests that it could grow by 23.2%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than iRhythm Technologies, Inc., analysts believe Integra LifeSciences Holdings Corp. is more attractive than iRhythm Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 IRTCiRhythm Technologies, Inc.11 2 0 -
Is IART or IRTC More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.075%.
-
Which is a Better Dividend Stock IART or IRTC?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or IRTC?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than iRhythm Technologies, Inc. quarterly revenues of $192.9M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.58x versus 8.02x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.58x 70.14x $402.1M -$5.4M IRTCiRhythm Technologies, Inc.8.02x -- $192.9M -$5.2M
-
Which has Higher Returns IART or MASI?
Masimo Corp. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of 14.46%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About IART or MASI?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 24.8%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 41.28%. Given that Masimo Corp. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Masimo Corp. is more attractive than Integra LifeSciences Holdings Corp..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 MASIMasimo Corp.4 3 0 -
Is IART or MASI More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.337%.
-
Which is a Better Dividend Stock IART or MASI?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or MASI?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Masimo Corp. quarterly revenues of $371.5M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than Masimo Corp.'s net income of $53.7M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.58x versus 4.11x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.58x 70.14x $402.1M -$5.4M MASIMasimo Corp.4.11x 116.80x $371.5M $53.7M
-
Which has Higher Returns IART or MMSI?
Merit Medical Systems, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of 7.22%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Merit Medical Systems, Inc.'s return on equity of 8.28%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B MMSIMerit Medical Systems, Inc.48.54% $0.46 $2.4B -
What do Analysts Say About IART or MMSI?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 24.8%. On the other hand Merit Medical Systems, Inc. has an analysts' consensus of $103.60 which suggests that it could grow by 17.54%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Merit Medical Systems, Inc., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Merit Medical Systems, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 MMSIMerit Medical Systems, Inc.4 1 0 -
Is IART or MMSI More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison Merit Medical Systems, Inc. has a beta of 0.617, suggesting its less volatile than the S&P 500 by 38.251%.
-
Which is a Better Dividend Stock IART or MMSI?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Merit Medical Systems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or MMSI?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Merit Medical Systems, Inc. quarterly revenues of $384.3M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is lower than Merit Medical Systems, Inc.'s net income of $27.8M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Merit Medical Systems, Inc.'s PE ratio is 45.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.58x versus 3.62x for Merit Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.58x 70.14x $402.1M -$5.4M MMSIMerit Medical Systems, Inc.3.62x 45.11x $384.3M $27.8M
-
Which has Higher Returns IART or TNDM?
Tandem Diabetes Care, Inc. has a net margin of -1.34% compared to Integra LifeSciences Holdings Corp.'s net margin of -8.49%. Integra LifeSciences Holdings Corp.'s return on equity of -37.15% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital IARTIntegra LifeSciences Holdings Corp.56.24% -$0.07 $3B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About IART or TNDM?
Integra LifeSciences Holdings Corp. has a consensus price target of $15.50, signalling upside risk potential of 24.8%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $24.81 which suggests that it could grow by 12.87%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IARTIntegra LifeSciences Holdings Corp.2 4 2 TNDMTandem Diabetes Care, Inc.7 13 0 -
Is IART or TNDM More Risky?
Integra LifeSciences Holdings Corp. has a beta of 1.025, which suggesting that the stock is 2.536% more volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.218%.
-
Which is a Better Dividend Stock IART or TNDM?
Integra LifeSciences Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra LifeSciences Holdings Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IART or TNDM?
Integra LifeSciences Holdings Corp. quarterly revenues are $402.1M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Integra LifeSciences Holdings Corp.'s net income of -$5.4M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Integra LifeSciences Holdings Corp.'s price-to-earnings ratio is 70.14x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra LifeSciences Holdings Corp. is 0.58x versus 1.46x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IARTIntegra LifeSciences Holdings Corp.0.58x 70.14x $402.1M -$5.4M TNDMTandem Diabetes Care, Inc.1.46x -- $249.3M -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
